Clinical trials
Phase 1 Pancreatic Neoplasms trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 10 |
| 2022 | 12 |
| 2023 | 5 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 70 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Betta Pharmaceuticals Co., Ltd. | 4 |
| Beijing Protgen Biotechnology Development Co., Ltd. | 2 |
| Fukushima Medical University | 2 |
| Minneamrita Therapeutics LLC | 2 |
| Shanghai YingLi Pharmaceutical Co. Ltd. | 2 |
| Shanghai Yunying Medical Technology | 2 |
| University Hospital, Geneva | 2 |
| Wellmarker Bio | 2 |
| Amsterdam UMC, location VUmc | 1 |
| Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pancreatic Neoplasms | 70 |
| Colorectal Neoplasms | 19 |
| Breast Neoplasms | 15 |
| Stomach Neoplasms | 14 |
| Ovarian Neoplasms | 11 |
| Lung Neoplasms | 9 |
| Head and Neck Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Neoplasm Metastasis | 7 |
| Prostatic Neoplasms | 7 |
Trials
Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.